P21

01 · What it is

P21’s own literature does not agree on how many amino acids it contains.

The 2010 paper that introduced it names the compound Ac-DGGLAG-NH2 and calls it P21 ¹. That sequence has six residues, and an independent 2023 review of peptide-based drugs for tauopathies repeats it in the same form ¹³. Papers from the originating laboratory a decade later call it P021 and describe it as a tetra-peptide derived from the biologically active region of human ciliary neurotrophic factor ^6,15. Both descriptions appear in the peer-reviewed record, from overlapping author groups, and no paper cited here reconciles them.

The most likely explanation is visible in the founding paper’s title, which is about neurotrophic peptides incorporating adamantane ¹ — and in its indexing, where the compound sits under adamantane analogues and derivatives. A four-residue peptide carrying an adamantane group would be described one way by a chemist counting amino acids and another way by an author writing out a parent sequence. But that is a reconstruction, not something any paper in this file states, and a reader trying to establish what molecule was actually administered cannot do so from the abstracts.

Where it came from. P021 is a small-molecule mimetic of ciliary neurotrophic factor, designed on the reasoning that neurotrophic factors themselves are unusable as drugs because they do not cross the blood-brain barrier, have short half-lives and carry severe side effects ⁶. The compound is intended to reproduce the useful part while escaping those liabilities, and its proposed mechanism runs through an increase in brain-derived neurotrophic factor expression rather than through CNTF signalling directly ¹⁵.

Who produced the evidence. Almost all of it comes from one laboratory: the Department of Neurochemistry at the New York State Institute for Basic Research in Developmental Disabilities on Staten Island, led by Khalid Iqbal ^{1,2,3,4,5,6,7,8,9,10,11,12,14}. Iqbal is a cofounder and Chief Scientific Officer of Phanes Biotech Inc., holds several patents on the composition and use of P021, and is developing it as a therapeutic — all of which he discloses ¹⁵.

The one substantially independent test found the mechanism did not hold in vivo. A group at the University of Bologna tested P021 in a model of CDKL5 deficiency disorder. In cultured human cells it worked: proliferation, survival and maturation deficits were restored, along with GSK3β signalling alterations. In the live animal it did not. The authors’ own word is unexpectedly — chronic in vivo treatment failed to increase BDNF levels, did not improve neuroanatomical defects, and produced only limited behavioural benefit ¹⁵.

BDNF is the proposed mechanism. This is a test of it in a living animal, by people who went looking for it, and it came back empty.

Sixteen years, six disease models, no human has ever received it.

02 · Evidence at a glance

Evidence grade

Preclinical — no published human study of any kind

Structure

Disputed within its own literature. Ac-DGGLAG-NH2, six residues, in the founding paper ¹; “tetra-peptide” in later papers from the same group ^6,15

Also written

P21 ¹ and P021 ^6,15 — used interchangeably in the record

Derived from

The biologically active region of human ciliary neurotrophic factor ^6,15

Chemical feature

Incorporates adamantane ¹

Proposed mechanism

Increased BDNF expression driving neurogenesis and synaptic plasticity ¹⁵

First publication

2010 ¹

Research concentration

One laboratory, Staten Island, on all but one paper ^1–12,14

Commercial interest

Iqbal is cofounder and CSO of Phanes Biotech Inc. and holds several patents on P021’s composition and use — disclosed ¹⁵

The independent in vivo test

Failed. No BDNF increase, no neuroanatomical improvement, limited behavioural benefit in Cdkl5 KO mice ¹⁵

That study’s in vitro result

Positive — proliferation, survival, maturation and GSK3β signalling restored in human CDKL5-KO cells ¹⁵

Disease models used

Alzheimer’s (3xTg-AD) ^3,7,11, cognitive aging ^2,4, Down syndrome (Ts65Dn) ⁸, age-related macular degeneration-like retinal pathology ⁹, prenatal and postnatal prevention ^10,11, CDKL5 deficiency ¹⁵

Human trials

None

Human safety data

None

Published toxicology

None located

US regulatory status

Not an approved drug; not a dietary supplement ingredient

03 · Mechanism of action

A CNTF mimetic that is not proposed to act through CNTF

The design logic is that neurotrophic factors are good targets and bad drugs. They do not cross the blood-brain barrier, they are cleared quickly, and given systemically they cause severe adverse effects ⁶. A small molecule reproducing the active region should escape all three problems.

What P021 is then proposed to do is not to substitute for CNTF at its receptor but to raise brain-derived neurotrophic factor expression, which in turn drives dentate gyrus neurogenesis and synaptic plasticity ¹⁵. The compound is a CNTF mimetic by derivation and a BDNF-elevating agent by proposed action.

That is a two-step mechanism, and each step needs separate evidence. The literature is much stronger on the downstream half — neurogenesis and plasticity are repeatedly measured — than on the step that connects the molecule to it.

The founding demonstration

Peripheral administration to normal adult C57BL/6 mice enhanced learning and both short-term and spatial reference memory, and increased neurogenesis and the maturation of newly born neurons in the granular cell layer and subgranular zone of the dentate gyrus ¹.

Peripheral dosing producing central effects is the claim that makes the compound interesting at all, and it was made in the first paper. Whether the compound itself reaches the brain, or acts on something peripheral that signals inward, is not established in the material cited here.

The mechanism was tested independently and did not replicate in vivo

In the Bologna study, human SH-CDKL5-KO cells responded to P021: proliferation, survival and maturation deficits were corrected, as were alterations in GSK3β signalling ¹⁵. Both young and adult Cdkl5 knockout mice then received chronic treatment. BDNF did not rise. Neuroanatomical defects did not improve. Behavioural benefit was limited ¹⁵.

The authors close by asking whether prenatal initiation or longer dosing would be needed to reproduce in animals what they saw in dishes ¹⁵.

A cell-culture result that does not survive the move into a living animal is the most common failure mode in this entire field, and here it happened to the proposed mechanism itself rather than to a downstream outcome. The study is also the clearest test in the file of whether the compound works outside the hands that invented it.

An unusually wide indication range for a preclinical compound

Alzheimer’s models ^3,7,11, normal cognitive aging ^2,4, Down syndrome ⁸, retinal degeneration resembling age-related macular degeneration ⁹, prenatal and early postnatal prevention paradigms ^10,11, and CDKL5 deficiency disorder ¹⁵.

A compound proposed to raise BDNF and increase neurogenesis will plausibly show something in almost any model where neurogenesis is impaired, which is most models of most brain disorders. Breadth of indication is not, by itself, evidence of strength — it can equally indicate an endpoint that is easy to move.

04 · Key research findings

The founding paper, 2010. Design of the peptidergic compound Ac-DGGLAG-NH2, called P21. Administered peripherally to normal adult C57BL/6 mice, it enhanced learning and both short-term and spatial reference memory, and enhanced neurogenesis and maturation of newly born neurons in the dentate gyrus ¹.

Normal mice, not a disease model. The starting claim is cognitive enhancement in healthy animals.

Cognitive aging, 2014. Chronic oral administration of P021 in a study framed around maintaining an appropriate microenvironment for neurogenesis and synaptic plasticity in age-associated memory dysfunction ².

Alzheimer’s model, 2014. Chronic oral treatment in the 3xTg-AD triple transgenic mouse, reported as disease-modifying ³.

Cerebrospinal fluid tau in aged rats, 2015. Elevated CSF tau in aged rats reduced by treatment ⁴.

A fluid biomarker rather than a behavioural endpoint, which is a different and in some ways harder kind of claim. It is also the project’s recurring pattern in miniature: a measured quantity moves.

Down syndrome model, 2017. Early neurotrophic pharmacotherapy in the Ts65Dn mouse, reported to rescue developmental delay and Alzheimer’s-like memory deficits ⁸.

Dendritic, synaptic and cognitive prevention, 2017. Two papers on prevention of dendritic and synaptic deficits and cognitive impairment ⁶, and on prevention of amyloid-β and tau pathologies, associated neurodegeneration and cognitive deficit with early treatment ⁷.

Retinal pathology, 2019. Photoreceptor degeneration, lipofuscin granules, vacuoles and retinal pigment epithelium atrophy in aged rats and 3xTg-AD mice, reported as prevented by chronic P021 ⁹.

An unexpected organ, and one of the more specific pathological descriptions in the file.

Developmental-window prevention, 2020 and 2021. Prenatal to early postnatal treatment reported to prevent Alzheimer-like behaviour and pathology in mice ¹⁰, and treatment initiated during early postnatal development reported to prevent Alzheimer-like behaviour and synaptic dysfunction ¹¹.

The framing here is that neurotrophic impairment during early development may itself be an etiopathogenic factor in Alzheimer’s disease ¹⁰ — a substantial hypothesis, resting on this compound’s effects in these models.

The independent test, 2024 — in vitro positive, in vivo negative. In human SH-CDKL5-KO cells, P021 restored proliferation, survival and maturation deficits and GSK3β signalling alterations. In Cdkl5 knockout mice, chronic treatment failed to increase BDNF, did not improve neuroanatomical defects, and gave limited behavioural benefit ¹⁵.

The University of Bologna group ran this; Iqbal is a co-author and the disclosure of his commercial position appears in the paper ¹⁵. The result is published as it came out, which is to the credit of everyone involved and is exactly the kind of paper this guide weights most heavily.

Imaging, 2026, with a correction. Diffusion MRI measures reported to detect brain microstructure changes from early P021 treatment in the 3xTg-AD mouse ¹⁶. The record carries no abstract. A corrigendum was published the following month ¹⁷.

Neither the finding nor what the correction changed can be established from the indexed record, and this guide does not characterise either.

05 · Evidence overview

06 · Safety profile

Animal data. No dedicated toxicology study appears in the indexed literature. What exists is incidental: chronic oral dosing was given over extended periods in aging and Alzheimer’s models ^2,3, and treatment was administered across prenatal and early postnatal windows ^10,11 without adverse findings being reported in the abstracts. Absence of reported harm in efficacy studies is not a safety assessment.

Human data. None. No published study of any design has administered P021 to a person.

What is genuinely unknown. What molecule is being discussed, at the level of precision a toxicologist would require — the structure is described two incompatible ways in the record ^1,6,15. Whether the compound crosses the blood-brain barrier itself or acts peripherally. Everything conventionally required before human exposure: repeat-dose toxicology, genotoxicity, carcinogenicity, reproductive toxicity, pharmacokinetics and dose-finding.

Two gaps deserve specific naming. The first is that the compound is proposed for administration during pregnancy and early development ^10,11 — a context in which the absence of reproductive and developmental toxicity data is not a routine gap but the central one. The second is that promoting neurogenesis and raising a growth factor is a proliferative intervention, and no carcinogenicity assessment appears anywhere in this file. Both are stated as missing data, not as evidence of harm.

And nothing is published on the identity or composition of any material sold under this name.

07 · US regulatory status

Current as of 6 September 2026. P21 is not an approved drug in the United States, is not a controlled substance, and is not a lawful dietary supplement ingredient. No marketing authorisation in any jurisdiction was identified for this guide.

The compound is under development by Phanes Biotech Inc. of Malvern, Pennsylvania, whose cofounder and Chief Scientific Officer holds several patents on its composition and use ¹⁵. This guide has not consulted patent records, corporate filings or clinical trial registries, and states nothing about development stage beyond what that disclosure says.

Under the World Anti-Doping Code, P21 does not appear as a named prohibited substance in the classes reviewed for this guide. Competitors should consult the current Prohibited List directly rather than rely on secondary summaries, including this one.

08 · Limitations of the evidence

1. The literature does not agree on the compound’s structure. The founding paper gives Ac-DGGLAG-NH2, six residues ¹; later papers from overlapping authors call it a tetra-peptide ^6,15. An adamantane group ¹ probably explains the discrepancy, but no paper cited here says so. A reader cannot establish from this record what molecule was administered.

1. No human has ever received it. Sixteen years, no trial, no pharmacokinetics, no safety cohort. The grade is Preclinical and nothing is close to moving it.

1. The proposed mechanism failed its one independent in vivo test. Chronic treatment did not raise BDNF in Cdkl5 knockout mice ¹⁵. BDNF elevation is the mechanism. A cell-culture result that does not survive transfer to a living animal is the field’s most common failure mode, and here it struck the load-bearing step.

1. Research concentration is close to total. One laboratory produced all but one of the papers cited here ^1–12,14, and its head holds the patents and an officership in the company developing the compound ¹⁵. The disclosure is exemplary; the concentration is still a limitation, because independent replication is what converts a promising result into a reliable one and there is almost none.

1. Animal-to-human translation is unattempted, and the models are among the field’s weakest predictors. 3xTg-AD ^3,7,11, Ts65Dn ⁸ and scopolamine-style cognitive assays have a poor record of predicting human outcomes across the whole Alzheimer’s field, independent of this compound.

1. The breadth of indications is not corroboration. Alzheimer’s, aging, Down syndrome, retinal degeneration and CDKL5 deficiency ^2,3,7,8,9,15 share a proposed common mechanism, so positive findings across them are correlated rather than independent. An endpoint that moves in every model may be an easy endpoint.

1. Publication bias cannot be assessed and is structurally likely. A compound developed inside a company by the laboratory that invented it generates unpublished data by default. The one clearly negative in vivo result in this file came from the collaboration with an outside group ¹⁵.

1. Absence of reported adverse effects is not safety data. No toxicology study exists. The compound is nonetheless proposed for prenatal and early postnatal administration ^10,11, where the evidentiary bar would ordinarily be highest.

1. A proliferative mechanism with no carcinogenicity assessment. Raising a growth factor and promoting neurogenesis is a proliferative intervention. Stated as a data gap, not a harm finding.

1. This guide has read abstracts, not full texts. In particular, the 2026 imaging paper carries no abstract at all ¹⁶ and its corrigendum’s content is not in the indexed record ¹⁷, so neither the finding nor the correction is characterised here.

1. Nothing is known about material sold under this name. No published analysis has examined the identity, purity or composition of any P21-labelled product.

09 · References

1. Li B, Wanka L, Blanchard J, Liu F, Chohan MO, Iqbal K, Grundke-Iqbal I. Neurotrophic peptides incorporating adamantane improve learning and memory, promote neurogenesis and synaptic plasticity in mice. FEBS Lett. 2010 Aug 4;584(15):3359–3365.

   PMID 20600002 ↗

2. Bolognin S, Buffelli M, Puoliväli J, Iqbal K. Rescue of cognitive-aging by administration of a neurogenic and/or neurotrophic compound. Neurobiol Aging. 2014 Sep;35(9):2134–2146.

   PMID 24702821 ↗

3. Kazim SF, Blanchard J, Dai CL, Tung YC, LaFerla FM, Iqbal IG, Iqbal K. Disease modifying effect of chronic oral treatment with a neurotrophic peptidergic compound in a triple transgenic mouse model of Alzheimer’s disease. Neurobiol Dis. 2014 Nov;71:110–130.

   PMID 25046994 ↗

4. Khatoon S, Chalbot S, Bolognin S, Puoliväli J, Iqbal K. Elevated tau level in aged rat cerebrospinal fluid reduced by treatment with a neurotrophic compound. J Alzheimers Dis. 2015;47(3):557–564.

   PMID 26401692 ↗

5. Kazim SF, Iqbal K. Neurotrophic factor small-molecule mimetics mediated neuroregeneration and synaptic repair: emerging therapeutic modality for Alzheimer’s disease. Mol Neurodegener. 2016 Jul 11;11(1):50.

   PMID 27400746 ↗

6. Kazim SF, Blanchard J, Bianchi R, Iqbal K. Early neurotrophic pharmacotherapy rescues developmental delay and Alzheimer’s-like memory deficits in the Ts65Dn mouse model of Down syndrome. Sci Rep. 2017 Apr 3;7:45561.

   PMID 28368015 ↗

7. Baazaoui N, Iqbal K. Prevention of dendritic and synaptic deficits and cognitive impairment with a neurotrophic compound. Alzheimers Res Ther. 2017 Jun 27;9(1):45.

   PMID 28655344 ↗

8. Baazaoui N, Iqbal K. Prevention of amyloid-beta and tau pathologies, associated neurodegeneration, and cognitive deficit by early treatment with a neurotrophic compound. J Alzheimers Dis. 2017;58(1):215–230.

   PMID 28387677 ↗

9. Liu Y, Wei W, Baazaoui N, Liu F, Iqbal K. Inhibition of AMD-like pathology with a neurotrophic compound in aged rats and 3xTg-AD mice. Front Aging Neurosci. 2019 Nov 19;11:309.

   PMID 31803044 ↗

10. Wei W, Wang Y, Liu Y, Dai CL, Tung YC, Liu F, Iqbal K. Prenatal to early postnatal neurotrophic treatment prevents Alzheimer-like behavior and pathology in mice. Alzheimers Res Ther. 2020 Aug 27;12(1):102.

    PMID 32854771 ↗

11. Wei W, Liu Y, Dai CL, Baazaoui N, Tung YC, Liu F, Iqbal K. Neurotrophic treatment initiated during early postnatal development prevents the Alzheimer-like behavior and synaptic dysfunction. J Alzheimers Dis. 2021;82(2):631–646.

    PMID 34057082 ↗

12. Baazaoui N, Iqbal K. Alzheimer’s disease: challenges and a therapeutic opportunity to treat it with a neurotrophic compound. Biomolecules. 2022 Oct 2;12(10):1409.

    PMID 36291618 ↗

13. Lozupone M, Dibello V, Sardone R, Castellana F, Zupo R, Lampignano L, Bortone I, Stallone R, Altamura M, Bellomo A, Daniele A, Solfrizzi V, Panza F. The development of peptide- and oligonucleotide-based drugs to prevent the formation of abnormal tau in tauopathies. Expert Opin Drug Discov. 2023 May;18(5):515–526.

    PMID 37042028 ↗

14. Iqbal K. Tau and Alzheimer’s disease: past, present and future. Cytoskeleton (Hoboken). 2024 Jan;81(1):116–121.

    PMID 38126608 ↗

15. Mottolese N, Loi M, Trazzi S, Tassinari M, Uguagliati B, Candini G, Iqbal K, Medici G, Ciani E. Effects of a ciliary neurotrophic factor (CNTF) small-molecule peptide mimetic in an in vitro and in vivo model of CDKL5 deficiency disorder. J Neurodev Disord. 2024 Nov 26;16(1):65.

    PMID 39592934 ↗

16. Falangola MF, Voltin J, Cole M, Nietert PJ, Liu F, Iqbal K, Jensen JH. Diffusion MRI measures detect brain microstructure changes due to early treatment with neurotrophic peptide mimetic P021 in the 3xTg-AD mouse model of Alzheimer’s disease. Magn Reson Imaging. 2026 Jun;129:110641. No abstract available..

    PMID 41740658 ↗

17. Falangola MF, Voltin J, Cole M, Nietert PJ, Liu F, Iqbal K, Jensen JH. Corrigendum to “Diffusion MRI measures detect brain microstructure changes due to early treatment with neurotrophic peptide mimetic P021 in the 3xTg-AD mouse model of Alzheimer’s disease”. Magn Reson Imaging. 2026 Jul;130:110677.

    PMID 41945082 ↗